Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
Wigal SB, Childress A, Berry SA, Belden H, Walters F, Chappell P, Sherman N, Orazem J, Palumbo D. Wigal SB, et al. Among authors: chappell p. J Child Adolesc Psychopharmacol. 2017 Oct;27(8):690-699. doi: 10.1089/cap.2016.0177. Epub 2017 May 30. J Child Adolesc Psychopharmacol. 2017. PMID: 28557548 Free PMC article. Clinical Trial.
Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study.
Wigal SB, Childress A, Berry SA, Belden HW, Chappell P, Wajsbrot DB, Nagraj P, Abbas R, Palumbo D. Wigal SB, et al. Among authors: chappell p. J Child Adolesc Psychopharmacol. 2018 Jun;28(5):314-321. doi: 10.1089/cap.2017.0138. Epub 2018 Mar 13. J Child Adolesc Psychopharmacol. 2018. PMID: 29641237 Free PMC article.
Re: "Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design, Definitions, and Ongoing Challenges for Child and Adolescent Psychopharmacology Research" by Strawn JR and Croarkin PE (J Child Adolesc Psychopharmacol 2018;28:(5)363).
Weihs KL, Wajsbrot DB, Chiles D, Ramaker S, Chappell P. Weihs KL, et al. Among authors: chappell p. J Child Adolesc Psychopharmacol. 2019 Apr;29(3):245-246. doi: 10.1089/cap.2018.0163. Epub 2019 Mar 15. J Child Adolesc Psychopharmacol. 2019. PMID: 30874454 No abstract available.
Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication Study.
Findling RL, Atkinson S, Bachinsky M, Raiter Y, Abreu P, Ianos C, Chappell P. Findling RL, et al. Among authors: chappell p. J Child Adolesc Psychopharmacol. 2022 Apr;32(3):143-152. doi: 10.1089/cap.2021.0121. Epub 2022 Apr 7. J Child Adolesc Psychopharmacol. 2022. PMID: 35394365 Clinical Trial.
189 results